Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.

STUDY OBJECTIVES We have previously shown that tiotropium at 18 mug reduces lung hyperinflation and dyspnea during exercise and improves exercise tolerance in patients with COPD. The present study was designed to gain further insight into the duration of improvements. DESIGN, PATIENTS, AND INTERVENTIONS A randomized, double-blind, placebo-controlled, parallel-group study was conducted in 261 COPD patients (mean age, 62.5 +/- 7.4 years [+/- SD]; 189 men and 72 women; mean FEV1, 1.2 +/- 0.4 L [43 +/- 12.7% predicted]). On day 0 (first dose), day 21, and day 42 of treatment, pulmonary function tests were performed before and 1 h 20 min after dosing, followed by a constant work rate cycle ergometry test (75% maximum work capacity) to symptom limitation at 2.25 h after dosing. On day 42, an additional constant work rate cycle ergometry test was performed at 8 h after dosing. RESULTS Adjusted mean (+/- SE) endurance time (ET) on day 42 was 803 +/- 40 s (tiotropium), vs 568 +/- 42 s (placebo) at 2.25 h after dosing (primary end point; treatment difference, 236 +/- 58 s; p = 0.0001) and 665 +/- 40 s (tiotropium) vs 494 +/- 42 s (placebo) at 8 h after dosing (treatment difference, 171 +/- 58 s; p = 0.0035). Adjusted mean dyspnea intensity at isotime on day 42 was 4.60 +/- 0.16 Borg units (tiotropium), vs 5.65 +/- 0.16 Borg units (placebo) at 2.25 h after dosing (p < 0.001), and 5.54 +/- 0.17 Borg units (tiotropium) vs 6.51 +/- 0.18 Borg units (placebo) at 8 h after dosing (p < 0.001). Adjusted mean pre-exercise inspiratory capacity (IC) on day 42 was 2.41 +/- 0.03 L (tiotropium) vs 2.19 +/- 0.03 L (placebo) at 2.25 h after dosing (p < 0.001), and 2.31 +/- 0.03 L (tiotropium) vs 2.16 +/- 0.03 L (placebo) at 8 h after dosing (p < 0.001). The significant increase in IC with tiotropium compared with placebo was maintained throughout exercise. CONCLUSIONS The present study confirms that tiotropium reduces lung hyperinflation at rest and during exercise, reduces exertional dyspnea, and improves symptom-limited exercise tolerance in COPD patients. Furthermore, this study shows that this improvement is present at 2.25 h and at 8 h after dosing after 6 weeks of treatment.

[1]  Sean Keenan,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.

[2]  Sean Keenan,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.

[3]  D. O’Donnell,et al.  Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[4]  D. O’Donnell,et al.  Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[5]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[6]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[7]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[8]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[9]  P. Calverley,et al.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.

[10]  P. Calverley,et al.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.

[11]  R. Ross,et al.  ATS/ACCP statement on cardiopulmonary exercise testing. , 2003, American journal of respiratory and critical care medicine.

[12]  F. Maltais,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003. , 2003, Canadian respiratory journal.

[13]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[14]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[15]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[16]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[17]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[18]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[19]  D. Postma,et al.  A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. , 2002, Chest.

[20]  D. Postma,et al.  A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. , 2002, Chest.

[21]  D. O’Donnell,et al.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[22]  D. O’Donnell,et al.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[24]  P. Jones,et al.  Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship. , 2000, American journal of respiratory and critical care medicine.

[25]  P. Jones,et al.  Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship. , 2000, American journal of respiratory and critical care medicine.

[26]  H. Ghezzo,et al.  Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. , 2000, The European respiratory journal.

[27]  H. Ghezzo,et al.  Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. , 2000, The European respiratory journal.

[28]  Bruce D. Johnson,et al.  Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. , 1999, Chest.

[29]  Bruce D. Johnson,et al.  Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. , 1999, Chest.

[30]  D. O’Donnell,et al.  Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[31]  D. O’Donnell,et al.  Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[32]  R. Casaburi,et al.  Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. , 1997, The European respiratory journal.

[33]  R. Casaburi,et al.  Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. , 1997, The European respiratory journal.

[34]  J Stocks,et al.  Measurement of lung volumes by plethysmography. , 1997, The European respiratory journal.

[35]  J Stocks,et al.  Measurement of lung volumes by plethysmography. , 1997, The European respiratory journal.

[36]  N. Jones,et al.  Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. , 1996, Chest.

[37]  N. Jones,et al.  Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. , 1996, Chest.

[38]  M. Belman,et al.  Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[39]  M. Belman,et al.  Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[40]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[41]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[42]  D. O’Donnell,et al.  Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. , 1993, The American review of respiratory disease.

[43]  D. O’Donnell,et al.  Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. , 1993, The American review of respiratory disease.

[44]  Diurnal variation in airflow obstruction in chronic bronchitis. , 1981, Thorax.

[45]  Diurnal variation in airflow obstruction in chronic bronchitis. , 1981, Thorax.